Jing et al., published that oncolytic measles virus targeting stromal uPAR and CD46 in colon cancer cells results in enhanced antitumor effects, supporting preclinical and clinical development of therapies based on stroma-directed systemically administered oncolytic viruses (Jing et al., 2020). This evidence concerns the gene PLAUR and colonic neoplasm.